{"filing":{"accession_number":"0001193125-26-375275","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-08-31","report_date":"2026-08-30","primary_document":"d110137d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/d110137d8k.htm"},"events":[{"id":30450,"run_id":27908,"accession_number":"0001193125-26-375275","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026, granting a non-exclusive, worldwide, royalty-bearing license to BioMarin's patents covering TransCon CNP (Yuviwel) for all indications including achondroplasia. The agreement resolves all pending patent litigation globally and provides for royalty payments of 20% of U.S. net sales and 18% of EU/Brazil/South Korea net sales until May 2030.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-08-31","form":"8-K","submitted_at":null,"items":[{"id":33047,"accession_number":"0001193125-26-375275","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026, granting a non-exclusive, worldwide, royalty-bearing license to BioMarin's patents covering \"TransCon CNP\" (Yuviwel) for all indications including achondroplasia. The agreement resolves all pending patent litigation globally, including before the U.S. ITC, and provides for royalty payments of 20% of U.S. net sales and 18% of EU/Brazil/South Korea net sales until May 2030. This constitutes a material definitive agreement under Item 1.01 involving a significant intellectual property license and settlement that resolves substantial litigation and creates ongoing financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:24.322064+00:00","company_name":"","ticker":null,"filing_date":""},{"id":33048,"accession_number":"0001193125-26-375275","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"BioMarin announced a global settlement with Ascendis Pharma resolving all pending patent-related proceedings, including a Section 337 investigation before the ITC and litigation pending in multiple jurisdictions (Brazil, Denmark, Germany, South Korea, and Northern District of California). The settlement includes a royalty arrangement (20% of U.S. net sales, 18% in EU/Brazil/South Korea through May 2030) and a license to BioMarin's CNP technology patents. This is a material resolution of significant intellectual property disputes that would affect investor assessment of the company's patent portfolio and future revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:24.322064+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33047,"accession_number":"0001193125-26-375275","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026, granting a non-exclusive, worldwide, royalty-bearing license to BioMarin's patents covering \"TransCon CNP\" (Yuviwel) for all indications including achondroplasia. The agreement resolves all pending patent litigation globally, including before the U.S. ITC, and provides for royalty payments of 20% of U.S. net sales and 18% of EU/Brazil/South Korea net sales until May 2030. This constitutes a material definitive agreement under Item 1.01 involving a significant intellectual property license and settlement that resolves substantial litigation and creates ongoing financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:24.322064+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-08-31"},{"id":33048,"accession_number":"0001193125-26-375275","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.85,"reasoning":"BioMarin announced a global settlement with Ascendis Pharma resolving all pending patent-related proceedings, including a Section 337 investigation before the ITC and litigation pending in multiple jurisdictions (Brazil, Denmark, Germany, South Korea, and Northern District of California). The settlement includes a royalty arrangement (20% of U.S. net sales, 18% in EU/Brazil/South Korea through May 2030) and a license to BioMarin's CNP technology patents. This is a material resolution of significant intellectual property disputes that would affect investor assessment of the company's patent portfolio and future revenue streams.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-31T11:00:24.322064+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-08-31"}]}